{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:12:51Z","timestamp":1778148771192,"version":"3.51.4"},"reference-count":65,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Background\/Objectives: Molecular tumor profiling has recently transformed oncologic care delivery, establishing precision medicine as an essential approach for defining cancer biology and revealing intratumoral heterogeneity. The growing accessibility of advanced nucleic acid sequencing technologies has created a demand for specialized expertise in interpreting comprehensive genomic profiling results. Academic institutions currently employ a strategy of conducting initial broad-spectrum genomic testing, followed by matching patients to investigational therapies targeting their specific genomic alterations. Consequently, molecular tumor boards (MTBs) have emerged predominantly within major cancer centers and academic medical institutions, providing the specialized knowledge necessary to translate precision oncology into routine clinical care. However, despite the substantial benefits of collaborative case review within tumor boards, clinicians frequently encounter multiple barriers to effective MTB implementation. Methods: this report examines these challenges performing an exploratory quantitative synthesis approach and explores implementation strategies and best practices derived from collective institutional experiences, with the goal of establishing a functional MTB at the local level and thereby expanding oncology patient access to cutting-edge therapeutic options.<\/jats:p>","DOI":"10.3390\/medsci14020242","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:03:37Z","timestamp":1778144617000},"page":"242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-5578","authenticated-orcid":false,"given":"Nicoleta Zenovia","family":"Antone","sequence":"first","affiliation":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaviu","family":"Andreicovici","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-7635","authenticated-orcid":false,"given":"Andrada Larisa","family":"Deac","sequence":"additional","affiliation":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Medical Oncology, Emergency Hospital Cluj-Napoca, 400535 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-3219","authenticated-orcid":false,"given":"Roxana","family":"Pintican","sequence":"additional","affiliation":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Department of Radiology, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Miclaus","sequence":"additional","affiliation":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Department of Genetic Explorations, \u201cProf. Dr. Ion Chiricuta\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-8643","authenticated-orcid":false,"given":"Adrian Pavel","family":"Trifa","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, Discipline of Medical Genetics, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Center of Expertise on Rare Pulmonary Diseases, Clinical Hospital of Infectious Diseases and Pneumophysiology \u201cDr. Victor Babes\u201d, 300310 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-348X","authenticated-orcid":false,"given":"Andreea","family":"Catana","sequence":"additional","affiliation":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Department of Genetic Explorations, \u201cProf. Dr. Ion Chiricuta\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"},{"name":"Department of Molecular Sciences, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-7103","authenticated-orcid":false,"given":"Ovidiu","family":"Balacescu","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Department of Genetic Explorations, \u201cProf. Dr. Ion Chiricuta\u201d Institute of Oncology, 400015 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103t\u0103lin","family":"Vlad","sequence":"additional","affiliation":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Department of Surgery, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9928-5883","authenticated-orcid":false,"given":"Patriciu","family":"Achimas-Cadariu","sequence":"additional","affiliation":[{"name":"\u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Breast Cancer Center, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"},{"name":"Department of Surgery, Institute of Oncology \u201cProf. Dr. Ion Chiricuta\u201d, 400015 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.molmed.2017.08.003","article-title":"Precision oncology: The road ahead","volume":"23","author":"Senft","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_2","first-page":"127","article-title":"The Drug Rediscovery Protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"Hoes","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.2016-0195","article-title":"Key lessons learned from Moffitt\u2019s precision medicine program: The Clinical Genomics Action Committee experience","volume":"22","author":"Knepper","year":"2017","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_5","first-page":"PO.18.00169","article-title":"Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results from a National Representative Survey of Oncologists in the United States","volume":"2","author":"Freedman","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_6","first-page":"144","article-title":"Next generation sequencing and the molecular tumor board from the point of view of oncologists","volume":"57","year":"2021","journal-title":"Cesk. Patol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5644\/ama2006-124.247","article-title":"Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital","volume":"48","author":"Trivedi","year":"2019","journal-title":"Acta Med. Acad."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2013-0405","article-title":"Molecular tumor board: The University of California-San Diego Moores Cancer Center experience","volume":"19","author":"Schwaederle","year":"2014","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1002\/cam4.5349","article-title":"Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study","volume":"12","author":"Shirota","year":"2023","journal-title":"Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"VanderWalde, A., Grothey, A., Vaena, D., Vidal, G., ElNaggar, A., Bufalino, G., and Schwartzberg, L. (2020). Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. J. Pers. Med., 10.","DOI":"10.3390\/jpm10040252"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2100524","DOI":"10.1200\/PO.21.00524","article-title":"Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial","volume":"6","author":"Miller","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1634\/theoncologist.2015-0097","article-title":"Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center","volume":"20","author":"Taffe","year":"2015","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1962","DOI":"10.1002\/onco.13936","article-title":"Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center","volume":"26","author":"Jain","year":"2021","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57845","DOI":"10.18632\/oncotarget.18471","article-title":"Implementation and utilization of the molecular tumor board to guide precision medicine","volume":"8","author":"Harada","year":"2017","journal-title":"Oncotarget"},{"key":"ref_15","first-page":"PO.16.00022","article-title":"Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board","volume":"1","author":"Burkard","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2000508","DOI":"10.1200\/PO.20.00508","article-title":"Real-World Data from a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients with Precision Medicine","volume":"6","author":"Charo","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2200030","DOI":"10.1200\/GO.22.00030","article-title":"Impact of Molecular Tumor Board on the Clinical Management of Patients with Cancer","volume":"8","author":"Behel","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hoefflin, R., Lazarou, A., Hess, M.E., Reiser, M., Wehrle, J., Metzger, P., Frey, A.V., Becker, H., Aumann, K., and Berner, K. (2021). Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. Cancers, 13.","DOI":"10.3390\/cancers13051151"},{"key":"ref_19","first-page":"PO.16.00046","article-title":"Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board","volume":"2017","author":"Dalton","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tarawneh, T.S., Rodepeter, F.R., Teply-Szymanski, J., Ross, P., Koch, V., Th\u00f6lken, C., Sch\u00e4fer, J.A., Gremke, N., Mack, H.I.D., and Gold, J. (2022). Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. Cancers, 14.","DOI":"10.3390\/cancers14184430"},{"key":"ref_21","first-page":"PO.21.00210","article-title":"Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer","volume":"5","author":"Huang","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/03008916211062266","article-title":"The molecular tumor board: A tool for the governance of precision oncology in the real world","volume":"108","author":"Incorvaia","year":"2022","journal-title":"Tumori"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2021.1115","article-title":"Recommendations for the Use of Next- Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group","volume":"54","author":"Yoon","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-025-00865-1","article-title":"Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps","volume":"9","author":"Gladstone","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s10147-020-01661-6","article-title":"Implementation of a molecular tumor board at a regional level to improve access to targeted therapy","volume":"25","author":"Bourien","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/1878-0261.13202","article-title":"Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience","volume":"16","author":"Louie","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JOP.2015.004127","article-title":"Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center","volume":"11","author":"Parker","year":"2015","journal-title":"J. Oncol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","article-title":"Lessons learned: The first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board","volume":"149","author":"Heinrich","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ijgc-2022-003425","article-title":"A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: The virtual experience of the MITO cooperative group","volume":"32","author":"Bartoletti","year":"2022","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jamiaopen\/ooz045","article-title":"A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients","volume":"2","author":"Pishvaian","year":"2019","journal-title":"JAMIA Open."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11523-023-00950-0","article-title":"Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board","volume":"18","author":"Dorman","year":"2023","journal-title":"Target Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41698-022-00309-0","article-title":"Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy","volume":"6","author":"Louie","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00174","DOI":"10.1016\/j.plabm.2020.e00174","article-title":"Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board","volume":"21","author":"Bernhardt","year":"2020","journal-title":"Pract. Lab. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1200\/PO.20.00008","article-title":"Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients with Non-Small-Cell Lung Cancer with Rare or Complex Mutational Profiles","volume":"4","author":"Koopman","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_36","first-page":"PO.18.00105","article-title":"Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience","volume":"2","author":"Hoefflin","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2200132","DOI":"10.1200\/PO.22.00132","article-title":"Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance","volume":"6","author":"Walters","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103567","DOI":"10.1016\/j.critrevonc.2021.103567","article-title":"The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM-SIAPEC\/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies","volume":"169","author":"Russo","year":"2022","journal-title":"Crit. Rev. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/10781552221091282","article-title":"Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation","volume":"29","author":"Peh","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41591-020-0969-2","article-title":"Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal","volume":"26","author":"Tamborero","year":"2020","journal-title":"Nat. Med."},{"key":"ref_41","first-page":"e461","article-title":"Tumor Boards: Optimizing the Structure and Improving Efficiency of Multidisciplinary Management of Patients with Cancer Worldwide","volume":"34","author":"Keating","year":"2014","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ctrv.2015.11.007","article-title":"The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature","volume":"42","author":"Pillay","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_43","first-page":"e12822","article-title":"Multidisciplinary work in oncology: Population-based analysis for seven invasive tumors","volume":"27","author":"Dubois","year":"2018","journal-title":"Eur. J. Cancer Care"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Milana, F., Famularo, S., Luberto, A., Rimassa, L., Scorsetti, M., Comito, T., Franzese, C., Poretti, D., Di Tommaso, L., and Personeni, N. (2022). Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastasis: A Single Center Review of 847 Patients. Cancers, 14.","DOI":"10.3390\/cancers14163952"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2217\/fon-2021-0471","article-title":"Implementing multidisciplinary tumor boards in oncology: A narrative review","volume":"18","author":"Mano","year":"2022","journal-title":"Future Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JOP.18.00661","article-title":"Implementing Precision Medicine in Community-Based Oncology Programs: Three Models","volume":"15","author":"Levit","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"110465","DOI":"10.1016\/j.isci.2024.110465","article-title":"Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy","volume":"27","author":"Louie","year":"2024","journal-title":"iScience"},{"key":"ref_48","first-page":"100775","article-title":"The impact of the multidisciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours","volume":"36","author":"Lam","year":"2023","journal-title":"Lancet Reg. Health West Pac."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2200649","DOI":"10.1200\/PO.22.00649","article-title":"Precision Oncology Working Group (POWG). Consensus statements on precision oncology in the China Greater Bay Area","volume":"7","author":"Lam","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Specchia, M.L., Frisicale, E.M., Carini, E., Di Pilla, A., Cappa, D., Barbara, A., Ricciardi, W., and Damiani, G. (2020). The impact of tumor board on cancer care: Evidence from an umbrella review. BMC Health Care Res., 20.","DOI":"10.1186\/s12913-020-4930-3"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Irreli, A., Ranieri, S.C., Di Giacomo, D., Malatesta, S., Patruno, L.V., Tessitore, A., Alesse, E., and Cannita, K. (2023). Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy. Cancers, 15.","DOI":"10.3390\/cancers15061727"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40164-022-00333-7","article-title":"Introducing AI to the molecular tumor board: One direction toward the establishment of precision medicine using large-scale cancer clinical and biological information","volume":"11","author":"Hamamoto","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100860","DOI":"10.1016\/j.currproblcancer.2022.100860","article-title":"Patient attendance at molecular tumor board: A new means of shared decision making?","volume":"46","author":"Cannon","year":"2022","journal-title":"Curr. Probl. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fonc.2020.00085","article-title":"The Multidisciplinary (MDT) Approach and Quality of Care","volume":"10","author":"Taberna","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oncolo\/oyac164","article-title":"Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board","volume":"28","author":"Green","year":"2023","journal-title":"Oncologist"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Vasseur, D., Sassi, H., Bayle, A., Tagliamento, M., Besse, B., Marzac, C., Arbab, A., Auger, N., Cotteret, S., and Aldea, M. (2022). Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test. Cells, 11.","DOI":"10.3390\/cells11121901"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ustjanzew, A., Desuki, A., Ritzel, C., Dolezilek, A.C., Wagner, D.C., Cristoph, J., Unberath, P., Kindler, T., Faber, J., and Marini, F. (2021). cbpManager: A web application to streamline the integration of clinical and genomic data in cBioPortal tu support the Molecular Tumor Board. BMC Med. Inform. Decis. Mak., 21.","DOI":"10.1186\/s12911-021-01719-z"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Fumagalli, C., Guerini-Rocco, E., and Barberis, M. (2021). Making the Most of Complexity to Create Opportunities: Comprehensive Genomic Profiling and Molecular Tumor Board for Patients with Non-Small Cell Lung Cancer (NSCLC). Cancers, 13.","DOI":"10.3390\/cancers13040609"},{"key":"ref_59","first-page":"139","article-title":"Challenges and Experiences Extending the cBioPortal for Cancer Genomics to a Molecular Tumor Board Platform","volume":"287","author":"Reimer","year":"2021","journal-title":"Stud. Health Technol. Inform."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Buechner, P., Hinderer, M., Unberath, P., Metzger, P., Boeker, M., Acker, T., Haller, F., Mack, E., Nowak, D., and Paret, C. (2020). Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal. Diagnostics, 10.","DOI":"10.3390\/diagnostics10020093"},{"key":"ref_61","first-page":"1161","article-title":"SPHN\/PHRT\u2014MedCo in Action: Empowering the Swiss Molecular Tumor Board with Privacy-Preserving and Real-Time Patient Discovery","volume":"270","author":"Raisaro","year":"2020","journal-title":"Stud. Health Technol. Inform."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13046-022-02512-0","article-title":"Bridging therapeutic opportunities: A survey by the Italian molecular tumor board workgroup of Alliance Against Cancer","volume":"41","author":"Ciliberto","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"104960","DOI":"10.1016\/j.critrevonc.2025.104960","article-title":"Extended molecular profiling in mesenchymal tumors: A consensus paper from the Italian Sarcoma Group","volume":"216","author":"Sbaraglia","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-022-00312-5","article-title":"MatchMiner: An open source platform for cancer precision medicine","volume":"6","author":"Klein","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"ref_65","first-page":"221","article-title":"OncoTree: A cancer classification system for precision oncology","volume":"5","author":"Smyth","year":"2021","journal-title":"JCO Clin. Cancer Inform."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:43:48Z","timestamp":1778147028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medsci14020242"],"URL":"https:\/\/doi.org\/10.3390\/medsci14020242","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}